News Releases

Below are the latest News Releases for Clearmind Medicine Inc.

31

January

2023

Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound

25

January

2023

Clearmind Medicine’s Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023

19

January

2023

Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company

17

January

2023

Israel-Based Clearmind Announces Additional Positive Results from the its Pre-Clinical Study for Cocaine Addiction Treatment

10

January

2023

Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial

5

January

2023

Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic-Derived Obesity Treatment in Pre-Clinical Trial

28

December

2022

Israel-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder

21

December

2022

Israel- Based Clearmind Medicine Granted U.S. Patent for Psychedelic-Based Alcohol Substitute

15

December

2022

Israeli Biotech Clearmind Medicine Inc's CEO, Dr. Adi Zuloff-Shani, Issues Letter to Shareholders

13

December

2022

Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100

9

December

2022

Israeli Biotech Clearmind Medicine Appoints ex-Red Bull Executive Special Advisor for Developing MEAI as Alcohol Substitute

23

November

2022

Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial

17

November

2022

Clearmind Medicine Announces Closing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market

11

October

2022

Clearmind Medicine Featured in "Psychedelics Tonight," Streaming on ALTRD.TV

22

September

2022

Clearmind Applies for Patent to Treat Obesity and Metabolic Syndrome